Literature DB >> 32425555

Phosphoproteomics Reveals Key Regulatory Kinases and Modulated Pathways Associated with Ovarian Cancer Tumors.

Yingchao Hu1, Lejia Sun2, Yinglan Zhang3, Jinghe Lang1, Jun Rao4.   

Abstract

BACKGROUND: Ovarian cancer (OC) is the seventh most common cancer worldwide for women. However, there are no sufficient diagnostic methods and few treatment options available due to poor understanding of its pathogenic mechanisms.
METHODS: To comprehensively analyze the phosphoproteomic characterization for OC, we took advantage of a quantitative global phosphoproteomics method, titanium(IV) immobilized metal affinity chromatography (Ti4+-IMAC) coupled to nanoscale liquid chromatography and quadrupole time-of-flight tandem mass spectrometry (nanoLC/Q-TOF-MS/MS) on ovarian tissue samples obtained from five OC patients and five matched controls.
RESULTS: A total of 722 phosphorylated sites corresponding to 534 proteins were significantly different (fold change ≥ 2, p < 0.01) between OC patients and the controls. Among them, 83 transcription factors mainly consisted of transcription cofactors, zf-C2H2, and chromatin remodeling factors and 29 kinases were included. Further functional analysis suggested significantly biological processes were highly enriched and involved in the pathogenesis of OC, especially fructose and mannose metabolism. Moreover, the regulatory roles of modulated pathways, including MAPK, ErbB, and GnRH signaling pathways were also identified as critical processes involved in OC. The results here highlighted key phosphorylated proteins, particularly kinases, and the corresponding cancer-related metabolic and signal pathways that played important roles in the development of OC. Additionally, the expression levels of two kinases, phosphorylated CDK (T14) and phosphorylated PRKCQ (S695), were validated by Western blot analysis in the other group of ovarian tissue samples.
CONCLUSION: Altogether, our data not only provided novel insights into the potential biomarkers and therapy options for OC but also extended our knowledge on its pathophysiological mechanism.
© 2020 Hu et al.

Entities:  

Keywords:  Ti4+-IMAC; biomarker; kinases; ovarian cancer; phosphoproteomics

Year:  2020        PMID: 32425555      PMCID: PMC7196812          DOI: 10.2147/OTT.S240164

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


  30 in total

1.  The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.

Authors:  P Cohen
Journal:  Eur J Biochem       Date:  2001-10

2.  Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.

Authors:  Md Tajmul; Farhat Parween; Lata Singh; Sandeep R Mathur; J B Sharma; Sunesh Kumar; D N Sharma; Savita Yadav
Journal:  Int J Biol Macromol       Date:  2017-12-06       Impact factor: 6.953

3.  Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets.

Authors:  Li-Rong Yu; Haleem J Issaq; Timothy D Veenstra
Journal:  Proteomics Clin Appl       Date:  2007-08-17       Impact factor: 3.494

4.  An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Authors:  Oded Kopper; Chris J de Witte; Kadi Lõhmussaar; Jose Espejo Valle-Inclan; Nizar Hami; Lennart Kester; Anjali Vanita Balgobind; Jeroen Korving; Natalie Proost; Harry Begthel; Lise M van Wijk; Sonia Aristín Revilla; Rebecca Theeuwsen; Marieke van de Ven; Markus J van Roosmalen; Bas Ponsioen; Victor W H Ho; Benjamin G Neel; Tjalling Bosse; Katja N Gaarenstroom; Harry Vrieling; Maaike P G Vreeswijk; Paul J van Diest; Petronella O Witteveen; Trudy Jonges; Johannes L Bos; Alexander van Oudenaarden; Ronald P Zweemer; Hugo J G Snippert; Wigard P Kloosterman; Hans Clevers
Journal:  Nat Med       Date:  2019-04-22       Impact factor: 53.440

5.  Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.

Authors:  Lin Zhang; Jia Huang; Nuo Yang; Shun Liang; Andrea Barchetti; Antonis Giannakakis; Mark G Cadungog; Ann O'Brien-Jenkins; Marco Massobrio; Katherine F Roby; Dionyssios Katsaros; Phyllis Gimotty; Ralf Butzow; Barbara L Weber; George Coukos
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

6.  Specific phosphopeptide enrichment with immobilized titanium ion affinity chromatography adsorbent for phosphoproteome analysis.

Authors:  Houjiang Zhou; Mingliang Ye; Jing Dong; Guanghui Han; Xinning Jiang; Renan Wu; Hanfa Zou
Journal:  J Proteome Res       Date:  2008-07-17       Impact factor: 4.466

7.  Phosphoproteome profiling revealed abnormally phosphorylated AMPK and ATF2 involved in glucose metabolism and tumorigenesis of GH-PAs.

Authors:  S Zhao; J Feng; C Li; H Gao; P Lv; J Li; Q Liu; Y He; H Wang; L Gong; D Li; Y Zhang
Journal:  J Endocrinol Invest       Date:  2018-04-24       Impact factor: 4.256

8.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

Authors:  Hui Zhang; Tao Liu; Zhen Zhang; Samuel H Payne; Bai Zhang; Jason E McDermott; Jian-Ying Zhou; Vladislav A Petyuk; Li Chen; Debjit Ray; Shisheng Sun; Feng Yang; Lijun Chen; Jing Wang; Punit Shah; Seong Won Cha; Paul Aiyetan; Sunghee Woo; Yuan Tian; Marina A Gritsenko; Therese R Clauss; Caitlin Choi; Matthew E Monroe; Stefani Thomas; Song Nie; Chaochao Wu; Ronald J Moore; Kun-Hsing Yu; David L Tabb; David Fenyö; Vineet Bafna; Yue Wang; Henry Rodriguez; Emily S Boja; Tara Hiltke; Robert C Rivers; Lori Sokoll; Heng Zhu; Ie-Ming Shih; Leslie Cope; Akhilesh Pandey; Bing Zhang; Michael P Snyder; Douglas A Levine; Richard D Smith; Daniel W Chan; Karin D Rodland
Journal:  Cell       Date:  2016-06-29       Impact factor: 41.582

9.  Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.

Authors:  Shuang Zhang; Igor Dolgalev; Tao Zhang; Hao Ran; Douglas A Levine; Benjamin G Neel
Journal:  Nat Commun       Date:  2019-11-26       Impact factor: 14.919

10.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Authors:  Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

View more
  2 in total

Review 1.  Phosphoproteomics: a valuable tool for uncovering molecular signaling in cancer cells.

Authors:  Jacqueline S Gerritsen; Forest M White
Journal:  Expert Rev Proteomics       Date:  2021-09-16       Impact factor: 4.250

Review 2.  The Emerging Function of PKCtheta in Cancer.

Authors:  Amandine Nicolle; Ye Zhang; Karine Belguise
Journal:  Biomolecules       Date:  2021-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.